ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ARGENX SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026
$825.61+6.47 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 42.2
- Dividend yield
- –
ARGENX SE revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 22 | % of revenue |
|---|---|---|
| United States | $94.35M | 98.3% |
| Japan | $1.51M | 1.6% |
| Other | $133.00K | 0.1% |
From the segment and revenue-disaggregation notes of Argenx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.